{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470477293
| IUPAC_name = (1''R'',2''R'',6''S'',7''S'')-4-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-4-azatricyclo[5.2.1.0<sup>2,6</sup>]decane-3,5-dione
| image = Tandospirone.svg
| width = 250

<!--Clinical data-->
| tradename =  Sediel
| Drugs.com = {{drugs.com|international|tandospirone}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism =  
| elimination_half-life = 2–3 hours (3–5 hours for metabolite {{abbrlink|1-PP|1-(2-pyrimidinyl)piperazine}})
| excretion = Urine (70%; 0.1% as unchanged drug)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 112457-95-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 91273
| IUPHAR_ligand = 55
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 82421
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 190230I669
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 274047

<!--Chemical data-->
| C=21 | H=29 | N=5 | O=2 
| molecular_weight = 383.487 g/mol
| smiles = O=C1N(C(=O)[C@H]3[C@@H]1[C@@H]2CC[C@H]3C2)CCCCN5CCN(c4ncccn4)CC5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CEIJFEGBUDEYSX-FZDBZEDMSA-N
| synonyms = Metanopirone
}}

'''Tandospirone''' (brand name '''Sediel''') is an [[anxiolytic]] and [[antidepressant]] [[drug]] used in [[China]] and [[Japan]], where it is marketed by [[Dainippon Sumitomo Pharma]]. It is a member of the [[azapirone]] class of drugs and is closely related to other azapirones like [[buspirone]] and [[gepirone]].

==Medical uses==

===Anxiety and depression===
Tandospirone is most commonly used as a treatment for anxiety and depressive disorders, such as [[generalised anxiety disorder]] and [[dysthymia]] respectively.<ref name = CNS/> For both indications it usually takes a couple of weeks for therapeutic effects to be start being seen,<ref name = CNS>{{cite journal|title=Tandospirone|journal=CNS Drugs|volume=5|issue=2|date=February 1996|pages=147–153|doi=10.2165/00023210-199605020-00006|format=PDF|author1=Barradell, LB |author2=Fitton, A }}</ref> although at higher doses more rapid anxiolytic responses have been seen.<ref name="pmid17516698">{{cite journal |pmid=17516698|year=2004 |author1=Nishitsuji |first2=H |first3=Y |first4=K |first5=D |first6=T |first7=C |first8=K |title=Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial |volume=24 |issue=2|pages=121–6 |journal=Clinical drug investigation |last2=To |last3=Murakami |last4=Kodama |last5=Kobayashi |last6=Yamada |last7=Kubo|last8=Mine|doi=10.2165/00044011-200424020-00007|format=PDF}}</ref> It has also been used successfully as a treatment for [[bruxism]].<ref name = MD>{{cite book|title=Tandospirone|work=Martindale: The Complete Drug Reference|publisher=The Royal Pharmaceutical Society of Great Britain|accessdate=14 November 2013|date=23 September 2011|url=http://www.medicinescomplete.com/mc/martindale/current/10442-w.htm}}</ref>

===Other uses===
Tandospirone has also been tried, successfully, as an adjunctive treatment for cognitive symptoms in schizophrenic individuals.<ref>{{cite journal|title=Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment|author1=Sumiyoshi, T |author2=Matsui, M |author3=Nohara, S |author4=Yamashita, I |author5=Kurachi, M |author6=Sumiyoshi, C |author7=Jayathilake, K |author8=Meltzer, HY |journal=The American Journal of Psychiatry|date=October 2001|volume=158|issue=10|pages=1722–1725|doi=10.1176/appi.ajp.158.10.1722|pmid=11579010|url=http://ajp.psychiatryonline.org/data/Journals/AJP/3729/1722.pdf|format=PDF}}</ref>

==Side effects==
Common adverse effects include:<ref name = CNS/>

* Dizziness
* Drowsiness
* Insomnia
* Headache
* Gastrointestinal disorders
* Dry mouth

Adverse effects with unknown frequency include:<ref name = CNS/>

* [[Hypotension]] (low blood pressure)
* [[Dysphoria]]
* [[Tachycardia]]
* [[Malaise]]
* Psychomotor impairment

It is not believed to be addictive but it is known to produce mild withdrawal effects (e.g. [[Anorexia (symptom)|anorexia]]) after abrupt discontinuation.<ref name = CNS/>

==Pharmacology==
Tandospirone acts as a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[partial agonist]], with a [[dissociation constant|K<sub>i</sub>]] [[affinity (pharmacology)|affinity]] value of 27 ± 5 nM<ref name="pmid1974152">{{cite journal |pmid=1974152 |year=1990 |author1=Hamik |first2=D |first3=C |first4=SJ |title=Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites |volume=28 |issue=2 |pages=99–109 |journal=Biological Psychiatry |doi=10.1016/0006-3223(90)90627-E |last2=Oksenberg |last3=Fischette |last4=Peroutka }}</ref> and approximately 55 to 85% [[intrinsic activity]].<ref name="pmid8745167">{{cite journal |pmid=8745167 |doi=10.1016/0306-3623(95)00077-1 |year=1995 |author1=Tanaka |first2=T |first3=H |first4=A |first5=Y |first6=M |title=Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain |volume=26 |issue=8 |pages=1765–72 |journal=General pharmacology |last2=Tatsuno |last3=Shimizu |last4=Hirose |last5=Kumasaka |last6=Nakamura}}</ref><ref name="journalEffects of tandospirone, a novel anxiolytic agent, on human 5-HT1...">{{cite journal |doi=10.1163/1569391041501933 |title=Effects of tandospirone, a novel anxiolytic agent, on human 5-HT<SUB>1A</SUB> receptors expressed in Chinese hamster ovary cells (CHO cells) |year=2004 |last1=Yabuuchi |first1=Kazuki |first2=Rie |first3=Yukihiro |journal=Biogenic Amines |volume=18 |pages=319 |last2=Tagashira |last3=Ohno |issue=3}}</ref> It has weak and clinically negligible affinity for the [[5-HT2A receptor|5-HT<sub>2A</sub>]] (1,300 ± 200), [[5-HT2A receptor|5-HT<sub>2C</sub>]] (2,600 ± 60), [[alpha-1 adrenergic|α<sub>1</sub>-adrenergic]] (1,600 ± 80), [[alpha-2 adrenergic|α<sub>2</sub>-adrenergic]] (1,900 ± 400), [[D1 receptor|D<sub>1</sub>]] (41,000 ± 10,000), and [[D2 receptor|D<sub>2</sub>]] (1,700 ± 300) [[receptor (biochemistry)|receptor]]s, and is essentially inactive at the [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], [[beta-adrenergic|β-adrenergic]], and [[muscarinic acetylcholine receptor]]s, [[serotonin transporter]], and [[benzodiazepine]] [[allosteric site]] of the [[GABAA receptor|GABA<sub>A</sub> receptor]] (all of which are > 100,000).<ref name="pmid1974152" /> There is evidence of tandospirone having low but significant [[antagonist]]ic activity at the [[alpha-2 adrenergic|α<sub>2</sub>-adrenergic receptor]] through its active [[metabolite]] [[1-(2-pyrimidinyl)piperazine]] (1-PP), however.<ref name="pmid1681447">{{cite journal |pmid=1681447 |year=1991 |author1=Blier |first2=O |first3=Y |first4=C |title=Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission |volume=30 |issue=7 |pages=691–701 |journal=Neuropharmacology |doi=10.1016/0028-3908(91)90176-C |last2=Curet |last3=Chaput |last4=De Montigny}}</ref><ref name="pmid1362206">{{cite journal |pmid=1362206 |year=1992 |author1=Miller |first2=ML |first3=JJ |first4=DJ |first5=A |title=Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine |volume=12 |issue=5 |pages=341–5 |journal=Journal of Clinical Psychopharmacology |last2=Thompson |last3=Byrnes |last4=Greenblatt |last5=Shemer |doi=10.1097/00004714-199210000-00009}}</ref>

==Society and culture==

===Name===
Tandospirone has also been known as '''metanopirone'''.

==References==
{{Reflist|2}}


{{Anxiolytics}}
{{Antidepressants}}
{{Adrenergic receptor modulators}}
{{Serotonin receptor modulators}}

[[Category:5-HT1A agonists]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]
[[Category:Azapirones]]
[[Category:Imides]]
[[Category:Piperazines]]
[[Category:Pyrimidines]]
[[Category:Cyclopentanes]]